IMHO, one path for Leo to consider is this. IP's real wealth at this time is the numerous patents for many indications already granted and the others still to be applied for. By licensing one or two indications to BPs here or elsewhere like South America, Europe or India, a cash flow would begin and funding for other trials can begin. The ultimate goal being the full deployment of Brilacidin, Kevetrin, and perhaps other molecules in the next generation of defensin mimetics and anticancer treatments.

I think that the sale of the company and all it's patents to BP will not realize the full value. I think it likely that offers have been floated and management has deferred, looking at the ultimate goal. Some offers might have been an attempt to eliminate competition against existing symptom treatments. Others were made in good faith but seriously undervalued.

Wishing GLTA and trying for patience awaiting the trial results.